BristolMyers wins major proxy advisor support for $90bn Celgene buy

Bristol-Myers wins major proxy advisor support for $90bn Celgene buy

10:18 EDT 29 Mar 2019 | Financial Times

Original Article: Bristol-Myers wins major proxy advisor support for $90bn Celgene buy

More From BioPortfolio on "Bristol-Myers wins major proxy advisor support for $90bn Celgene buy"